DE602006013821D1 - D ezetimibe - Google Patents

D ezetimibe

Info

Publication number
DE602006013821D1
DE602006013821D1 DE602006013821T DE602006013821T DE602006013821D1 DE 602006013821 D1 DE602006013821 D1 DE 602006013821D1 DE 602006013821 T DE602006013821 T DE 602006013821T DE 602006013821 T DE602006013821 T DE 602006013821T DE 602006013821 D1 DE602006013821 D1 DE 602006013821D1
Authority
DE
Germany
Prior art keywords
oxygen
ezetimibe
present
compositions
simvastatin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602006013821T
Other languages
English (en)
Inventor
Vesna Kroselj
Renata Lakse
Rebeka Toporisic
Joze Kastelic
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KRKA dd
Original Assignee
KRKA Tovarna Zdravil dd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34937786&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE602006013821(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by KRKA Tovarna Zdravil dd filed Critical KRKA Tovarna Zdravil dd
Publication of DE602006013821D1 publication Critical patent/DE602006013821D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrane Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Dental Preparations (AREA)
  • Adhesives Or Adhesive Processes (AREA)
DE602006013821T 2005-07-06 2006-06-30 D ezetimibe Active DE602006013821D1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05014680A EP1741427A1 (de) 2005-07-06 2005-07-06 Pharmazeutische Zusammensetzung enthaltend Simvastatin und Ezetimibe
PCT/EP2006/006369 WO2007003365A1 (en) 2005-07-06 2006-06-30 Pharmaceutical composition comprising simvastatin and ezetimibe

Publications (1)

Publication Number Publication Date
DE602006013821D1 true DE602006013821D1 (en) 2010-06-02

Family

ID=34937786

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602006013821T Active DE602006013821D1 (en) 2005-07-06 2006-06-30 D ezetimibe

Country Status (17)

Country Link
US (1) US8921352B2 (de)
EP (2) EP1741427A1 (de)
AT (1) ATE464882T1 (de)
CA (1) CA2614347A1 (de)
DE (1) DE602006013821D1 (de)
DK (1) DK1901736T3 (de)
EA (1) EA013266B1 (de)
ES (1) ES2341731T3 (de)
HR (1) HRP20100282T1 (de)
NO (1) NO340496B1 (de)
PL (1) PL1901736T3 (de)
PT (1) PT1901736E (de)
RS (1) RS51338B (de)
SI (1) SI1901736T1 (de)
UA (1) UA90521C2 (de)
WO (1) WO2007003365A1 (de)
ZA (1) ZA200800111B (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7871998B2 (en) 2003-12-23 2011-01-18 Astrazeneca Ab Diphenylazetidinone derivatives possessing cholesterol absorption inhibitory activity
UY29607A1 (es) 2005-06-20 2007-01-31 Astrazeneca Ab Compuestos quimicos
SA06270191B1 (ar) 2005-06-22 2010-03-29 استرازينيكا ايه بي مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم
AR057072A1 (es) 2005-06-22 2007-11-14 Astrazeneca Ab Compuestos quimicos derivados de 2-azetidinona, formulacion farmaceutica y un proceso de preparacion del compuesto
AR060623A1 (es) 2006-04-27 2008-07-02 Astrazeneca Ab Compuestos derivados de 2-azetidinona y un metodo de preparacion
EP2120882A2 (de) * 2007-02-23 2009-11-25 Krka Pharmazeutische zusammensetzung mit einem cholesterinabsorptionshemmer
WO2009024889A2 (en) * 2007-08-21 2009-02-26 Ranbaxy Laboratories Limited Pharmaceutical composition comprising a hmg-coa reductase inhibitor and ezetimibe
EP2217214B1 (de) 2007-12-10 2017-07-19 ratiopharm GmbH Pharmazeutische formulierung mit ezetimib
WO2009077573A2 (en) * 2007-12-17 2009-06-25 Krka, Tovarna Zdravil, D.D., Novo Mesto Suspension comprising non-micronized ezetimibe micro-particles
TR200806302A2 (tr) * 2008-08-22 2010-03-22 Bi̇lgi̇ç Mahmut Çözünürlük ve stabilite artırıcı farmasötik formülasyon.
TR200806300A2 (tr) * 2008-08-22 2010-03-22 B�Lg�� Mahmut Çözünürlük artırıcı farmasötlk formulasyon
MX344885B (es) * 2008-11-10 2017-01-10 Psicofarma S A De C V Proceso para la obtencion de una composicion de rosuvastatina calcica y producto obtenido.
EP2204170A1 (de) 2008-12-01 2010-07-07 LEK Pharmaceuticals D.D. Pharmazeutische Zusammensetzung mit Ezetimibe und Simvastatin
EP2216016A1 (de) 2009-02-06 2010-08-11 LEK Pharmaceuticals d.d. Verfahren zur Herstellung einer pharmazeutischen Zusammensetzung, die Ezetimib umfasst
WO2011002424A2 (en) 2009-07-02 2011-01-06 Bilgic Mahmut Solubility and stability enchancing pharmaceutical formulation
WO2011019326A2 (en) * 2009-07-02 2011-02-17 Mahmut Bilgic Solubility and stability enchancing pharmaceutical formulation
EP2448564A2 (de) * 2009-07-02 2012-05-09 Bilgic Mahmut Löslichkeitsverstärkende pharmazeutische formulierung
EP2368543A1 (de) 2010-03-25 2011-09-28 KRKA, tovarna zdravil, d.d., Novo mesto Verfahren zur Herstellung einer granulierten pharmazeutischen Zusammensetzung mit Simvastatin und/oder Ezetimibe
EP2468258A1 (de) 2010-12-22 2012-06-27 LEK Pharmaceuticals d.d. Verfahren zur Herstellung einer pharmazeutischen Zusammensetzung, die einen wenig löslichen, pharmazeutisch wirksamen Bestandteil umfasst
AR086675A1 (es) * 2011-06-14 2014-01-15 Merck Sharp & Dohme Composiciones farmaceuticas de combinaciones de inhibidores de la dipeptidil peptidasa-4 con simvastatina
CN102266323B (zh) * 2011-08-04 2013-03-27 海南锦瑞制药股份有限公司 依折麦布和辛伐他汀组合物及其制备方法
KR102578578B1 (ko) * 2016-02-03 2023-09-14 삼성전자주식회사 암모니아수 내의 불순물 검출방법
JP7115825B2 (ja) * 2017-06-28 2022-08-09 日医工株式会社 エゼチミブ含有経口製剤及びその製造方法
JP2019014700A (ja) * 2017-07-11 2019-01-31 大原薬品工業株式会社 エゼチミブ含有口腔内崩壊錠及びその製造方法
PL425975A1 (pl) * 2018-06-19 2020-01-02 Invest Bielany Spółka Z Ograniczoną Odpowiedzialnością Złożona kompozycja farmaceutyczna do leczenia dyslipidemii i sposób jej wytwarzania
WO2022023206A1 (en) * 2020-07-27 2022-02-03 Krka, D.D., Novo Mesto Bilayer tablet comprising ezetimibe and atorvastatin
CN115227659B (zh) * 2022-08-19 2023-05-02 北京百奥药业有限责任公司 一种依折麦布辛伐他汀组合物及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU548996B2 (en) 1980-02-04 1986-01-09 Merck & Co., Inc. Tetrahydro-2h-pyran-2-one derivatives
US4820850A (en) 1987-07-10 1989-04-11 Merck & Co., Inc. Process for α-C-alkylation of the 8-acyl group on mevinolin and analogs thereof
US4916239A (en) 1988-07-19 1990-04-10 Merck & Co., Inc. Process for the lactonization of mevinic acids and analogs thereof
US5631365A (en) * 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
US6235311B1 (en) * 1998-03-18 2001-05-22 Bristol-Myers Squibb Company Pharmaceutical composition containing a combination of a statin and aspirin and method
CN100509058C (zh) * 2001-01-26 2009-07-08 先灵公司 过氧化物酶体增殖物激活受体(ppar)活化剂和甾醇吸收抑制剂的组合药以及对于血管适应症的治疗
EP1241110A1 (de) * 2001-03-16 2002-09-18 Pfizer Products Inc. Ausgabeeinheit für sauerstoff-empfindlichen Medikamenten
US6669955B2 (en) * 2001-08-28 2003-12-30 Longwood Pharmaceutical Research, Inc. Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
WO2003055467A1 (en) * 2001-12-18 2003-07-10 Synthon B.V. Simvastatin dosage forms
AR040588A1 (es) * 2002-07-26 2005-04-13 Schering Corp Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
SI21400A (sl) * 2003-02-12 2004-08-31 LEK farmacevtska družba d.d. Stabilna farmacevtska oblika z inhibitorjem HMG-CoA reduktaze
AU2003259547A1 (en) 2003-07-31 2005-02-14 Hetero Drugs Limited Ezetimibe polymorphs
PL379195A1 (pl) * 2003-08-05 2006-07-24 Zentiva, A.S. Sposoby stabilizacji atorwastatyny
US20060223882A1 (en) * 2005-03-23 2006-10-05 Venkataraman Sundaram Amorphous simvastatin

Also Published As

Publication number Publication date
NO340496B1 (no) 2017-05-02
SI1901736T1 (sl) 2010-08-31
ES2341731T3 (es) 2010-06-25
EP1901736A1 (de) 2008-03-26
RS51338B (en) 2011-02-28
ATE464882T1 (de) 2010-05-15
UA90521C2 (uk) 2010-05-11
WO2007003365A1 (en) 2007-01-11
US20080300233A1 (en) 2008-12-04
NO20080627L (no) 2008-04-02
EP1741427A1 (de) 2007-01-10
HRP20100282T1 (hr) 2010-07-31
EA013266B1 (ru) 2010-04-30
CA2614347A1 (en) 2007-01-11
ZA200800111B (en) 2008-12-31
US8921352B2 (en) 2014-12-30
DK1901736T3 (da) 2010-08-16
PL1901736T3 (pl) 2010-09-30
PT1901736E (pt) 2010-05-31
EA200702416A1 (ru) 2008-04-28
EP1901736B1 (de) 2010-04-21

Similar Documents

Publication Publication Date Title
DE602006013821D1 (en) D ezetimibe
EA201390409A1 (ru) Составы с низкой дозой панкрелипазы и кишечно-растворимым покрытием
JP2010532765A5 (de)
WO2008092006A3 (en) Antimicrobial compositions
WO2007051811A3 (en) Pharmaceutical use of substituted amides
UA94901C2 (ru) Антибактериальные производные пиперидина
BR0314612A (pt) Composição farmacêutica estabilizada, contendo excipientes básicos
MY147373A (en) Piperazine derivatives as antimalarial agents
MY150958A (en) Compounds for the treatment of multi-drug resistant bacterial infections
HK1084582A1 (en) Stable solid medicinal composition for oral administration
WO2007112000A3 (en) Treatment of pain
WO2010030180A3 (en) Peptide formulations and uses thereof
EP2392322A3 (de) Dosierschemata für Trans-Clomiphen
TW200806300A (en) New therapeutic combinations for the treatment of depression
WO2007112272A3 (en) Formulations of low dose diclofenac and beta-cyclodextrin
UA102187C2 (ru) Фармацевтическая композиция для пероральной доставки дииндолилметана
IL192611A0 (en) Biologically active composition comprising ethylcellulose
TW200736203A (en) New pleuromutilin derivative and its use
EP2801359A3 (de) Verwendung von Nikotin zur Behandlung von Sepsis bei Menschen durch Antibiotikum
EP1713439B1 (de) Pharmazeutisches präparat für die mundhöhle
WO2007138233A3 (fr) Utilisation du zatosetron pour le traitement de la rosacee
MY174362A (en) Nephelium lappaceum extracts for cosmeceutical and nutraceutical applications
CY1110814T1 (el) Νεα υποκατεστημενα αρυλοεξαδιενικα οξεα και εστερες αυτων τα οποια μπορουν να χρησιμοποιηθουν για την αγωγη και προληψη του διαβητη, δυσλιπιδαιμιας και αθηροσκληρωσης, φαρμακευτικες συνθεσεις που τα περιλαμβανουν και διεργασιες για την παρασκευη αυτων
HRP20090102T3 (en) Improved pharmaceutical composition containing ace inhibitor and method for the preparation thereof
MX2009002254A (es) Dosis de bifeprunox para tratar esquizofrenia.

Legal Events

Date Code Title Description
8363 Opposition against the patent